Loading clinical trials...
Loading clinical trials...
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors
Conditions
Interventions
LM-302
Locations
7
United States
Local Institution - 0013
Duarte, California, United States
Local Institution - 0017
Fullerton, California, United States
Local Institution - 0012
Lafayette, Indiana, United States
Local Institution - 0020
Paramus, New Jersey, United States
Local Institution - 0018
New York, New York, United States
Local Institution - 0016
Oklahoma City, Oklahoma, United States
Start Date
December 29, 2021
Primary Completion Date
January 4, 2024
Completion Date
January 4, 2024
Last Updated
April 17, 2024
NCT06898450
NCT05720117
NCT05719558
NCT05098132
NCT07477743
NCT04585750
Lead Sponsor
Turning Point Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions